IQVIA Virtual Trial Solutions Used in More than 60 Trials
March 09 2021 - 8:00AM
Business Wire
To date, IQVIA has enrolled more than 150,000
subjects across 10 therapy areas
IQVIA™ (NYSE:IQV) announced today that more than 60 trials
spanning over 40 countries utilize its innovative decentralized
clinical trial solutions as part of their respective registration
trials. Many of these trials, launched in 2020 as virtual and
patient-centric solutions, are providing business continuity
measures to sponsors during the global pandemic. This milestone
reflects the growing need for flexibility in clinical research and
the proliferation of technology-enabled options that enable
decentralized trials.
“Patient-centricity is at the core of decentralized and hybrid
trial design. We used to bring the patient to the trial, but now we
bring the trial to the patient,” said Costa Panagos, president,
R&D Operations, IQVIA. “The idea is to design trials that fit
into patients’ lives in a way that is seamless with their
day-to-day activities and to capture important trial information,
while reducing the burden on patients and investigators alike. It
also means we adapt the way we support investigative sites globally
with our study concierge service and other white glove
solutions.”
IQVIA’s virtual model offers the adaptability necessary to meet
a sponsor’s operational requirements. The solution is supported by
a range of IQVIA capabilities including direct-to-patient
engagement, telehealth technologies, virtual site management, and
home health nursing.
IQVIA is currently managing a mix of fully virtual trials and
hybrid trials for several clients including five of the top-10
pharma companies globally, enrolling more than 150,000 subjects in
a range of therapy areas since inception. Those areas of
investigational clinical research include: COVID-19 vaccines and
treatments, immunology, central nervous system disorders,
cardiovascular, oncology, dermatology, and various infectious
diseases.
ABOUT IQVIA
IQVIA (NYSE:IQV) is a leading global provider of advanced
analytics, technology solutions, and clinical research services to
the life sciences industry. IQVIA creates intelligent connections
across all aspects of healthcare through its analytics,
transformative technology, big data resources and extensive domain
expertise. IQVIA Connected Intelligence™ delivers powerful insights
with speed and agility — enabling customers to accelerate the
clinical development and commercialization of innovative medical
treatments that improve healthcare outcomes for patients. With
approximately 70,000 employees, IQVIA conducts operations in more
than 100 countries.
IQVIA is a global leader in protecting individual patient
privacy. The company uses a wide variety of privacy-enhancing
technologies and safeguards to protect individual privacy while
generating and analyzing information on a scale that helps
healthcare stakeholders identify disease patterns and correlate
with the precise treatment path and therapy needed for better
outcomes. IQVIA’s insights and execution capabilities help biotech,
medical device and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders tap
into a deeper understanding of diseases, human behaviours and
scientific advances, in an effort to advance their path toward
cures. To learn more, visit www.iqvia.com.
IQVIAFIN
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210309005020/en/
Tor Constantino, IQVIA Media Relations
(tor.constantino@iqvia.com) +1.484.567.6732
Andrew Markwick, IQVIA Investor Relations
(andrew.markwick@iqvia.com) +1.973.257.7144
IQVIA (NYSE:IQV)
Historical Stock Chart
From Mar 2024 to Apr 2024
IQVIA (NYSE:IQV)
Historical Stock Chart
From Apr 2023 to Apr 2024